Albert David Appoints New CEO, Recommends ₹5 Dividend Amid ₹1.49 Cr FY26 Loss

HEALTHCAREBIOTECH
Whalesbook Corporate News Logo
AuthorAarav Shah|Published at:
Albert David Appoints New CEO, Recommends ₹5 Dividend Amid ₹1.49 Cr FY26 Loss
Overview

Albert David approved its FY26 audited results, reporting a ₹1.49 crore net loss compared to a profit last year. The company appointed Amit Mahla as its new CEO and recommended a ₹5 per share final dividend, pending shareholder approval, signaling a potential strategic shift.

Instant Stock Alerts on WhatsApp

Used by 10,000+ active investors

1

Add Stocks

Select the stocks you want to track in real time.

2

Get Alerts on WhatsApp

Receive instant updates directly to WhatsApp.

  • ✓Quarterly Results
  • ✓Concall Announcements
  • ✓New Orders & Big Deals
  • ✓Capex Announcements
  • ✓Bulk Deals
  • ✦And much more
Add StocksGet it on Google PlayDownload on the App Store

Albert David Posts FY26 Net Loss, Appoints New CEO and Recommends Dividend

Albert David Ltd has reported a net loss of ₹1.49 crore for the financial year ending March 31, 2026. This marks a significant reversal from the ₹17.20 crore profit the Indian pharmaceutical company achieved in the previous fiscal year. The company announced these results alongside the appointment of Amit Mahla as its new Chief Executive Officer and a recommendation for a final dividend of ₹5 per share.

The board approved the audited financial results for FY26 during a meeting on May 12, 2026. While revenues for FY26 stood at ₹333.60 crore, comparable to FY25's ₹345.77 crore, a substantial loss before tax of ₹25.23 crore in the quarter ended March 31, 2026, heavily impacted the full-year outcome. In contrast, FY25 had reported revenues of ₹333.63 crore and a profit of ₹14.48 crore.

The appointment of Amit Mahla as CEO is seen as a strategic leadership move, potentially signaling a new direction for the company. Investors will be looking to his leadership to navigate current market conditions and drive future growth.

Shareholders are set to receive a final dividend of ₹5 per share, provided it receives approval at the upcoming Annual General Meeting. This payout offers a direct return to investors despite the company's annual net loss.

Albert David, an Indian pharmaceutical firm manufacturing and marketing formulations, has seen past market reports hint at potential business demergers separating its pharmaceutical and real estate segments. News from May 2024 also suggested possible changes within the promoter group, setting a backdrop for leadership transitions.

The company also re-appointed its auditors, M/s. PricewaterhouseCoopers Services LLP and M/s. S. Gupta & Co., for internal and cost audit functions respectively for FY 2026-27.

Shareholders will vote on the dividend at the 87th Annual General Meeting scheduled for August 6, 2026. Investors will be closely watching the company's strategic initiatives under its new CEO, its future financial results, and any further updates on previously reported demerger plans.

Get stock alerts instantly on WhatsApp

Quarterly results, bulk deals, concall updates and major announcements delivered in real time.

Add Stocks
Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.